0.2555  0.005 (1.98%)		07-26 15:00
Open: 0.2555 High: 0.2555 Volume: 100		Pre. Close: 0.25055 Low: 0.2555 Market Cap: 1(M)

Short term
Mid term
Targets	6-month :	0.37	1-year :	0.6
Resists	First :	0.31	Second :	0.51
Pivot price	0.22
Supports	First :	0	Second :	0
MAs	MA(5) :	0.23	MA(20) :	0.27
	MA(100) :	0.69	MA(250) :	1.29
MACD	MACD :	-0.1	Signal :	-0.2
%K %D	K(14,3) :	76.5	D(3) :	61.5
RSI	RSI(14): 36.1
52-week	High :	3.47	Low :	0

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CWBR ] has closed below upper band by 14.5%. Bollinger Bands are 69.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.26 - 0.26	0.26 - 0.26
Low:	0.25 - 0.25	0.25 - 0.26
Close:	0.25 - 0.26	0.26 - 0.26

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.

Sat, 20 Jul 2024
CohBar (NASDAQ:CWBR) Trading 20.3% Higher - American Banking and Market News

Tue, 26 Dec 2023
Delisting of Securities of SmileDirectClub, Inc.; Bellerophon Therapeutics, Inc.; Elys Game Technology, Corp.’; Athersys, Inc.; Borqs Technologies, Inc.; ContraFect Corporation; CohBar, Inc.; AgileThought, Inc.; Fat Projects Acquisition Corp.; Evelo Biosciences, - StockTitan

Tue, 23 May 2023
CWBR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of CohBar, Inc. Is Fair to Shareholders - Business Wire

Tue, 23 May 2023
CohBar Stock Doubles: Company Agrees To Merge With Morphogenesis To Advance Late-Stage Oncology Candidates - Yahoo Finance

Mon, 26 Sep 2022
7 Nasdaq Stocks to Sell Before They Die - InvestorPlace

Fri, 23 Apr 2021
CohBar: A Promising Early Pureplay On Mitochondrial-Based Therapeutics (CWBR) - Seeking Alpha

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Outperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	3 (M)
Shares Float	2 (M)
Held by Insiders	15 (%)
Held by Institutions	6.2 (%)
Shares Short	15 (K)
Shares Short P.Month	29 (K)

EPS	-4.37
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	3.26
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-48.4 %
Return on Equity (ttm)	-84 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-4.48
Qtrly Earnings Growth	0 %
Operating Cash Flow	-8 (M)
Levered Free Cash Flow	-4 (M)

PE Ratio	-0.06
PEG Ratio	0
Price to Book value	0.07
Price to Sales	0
Price to Cash Flow	-0.1

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.